Table 3 Lenalidomide discontinuations and dose modifications (safety population)a.

From: Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA

 

Non-frailb

Frail

 

Fit (19.9%c; n = 145/729)

Intermediate (34.3%c; n = 250/729)

Total–non-frailb (54.2%c; n = 395/729)

Frail (45.8%c; n = 334/729)

 

D-Rd (18.7%d; n = 68/364)

Rd (21.1%e; n = 77/365)

D-Rd (35.2%d; n = 128/364)

Rd (33.4%e; n = 122/365)

D-Rd (53.8%d; n = 196/364)

Rd (54.5%e; n = 199/365)

D-Rd (46.2%d; n = 168/364)

Rd (45.5%e; n = 166/365)

Lenalidomide permanent discontinuation, n (%)

13 (19.1)

8 (10.4)

24 (18.8)

17 (13.9)

37 (18.9)

25 (12.6)

45 (26.8)

23 (13.9)

 Reason for discontinuation, n (%)

        

  AE

12 (17.6)

5 (6.5)

18 (14.1)

6 (4.9)

30 (15.3)

11 (5.5)

37 (22.0)

14 (8.4)

  Other

1 (1.5)

3 (3.9)

6 (4.7)

11 (9.0)

7 (3.6)

14 (7.0)

8 (4.8)

9 (5.4)

Lenalidomide dose delay, n (%)

13 (19.1)

7 (9.1)

15 (11.7)

11 (9.0)

28 (14.3)

18 (9.0)

31 (18.5)

13 (7.8)

 Reason for delay, n (%)

        

  AE

7 (10.3)

3 (3.9)

8 (6.3)

5 (4.1)

15 (7.7)

8 (4.0)

14 (8.3)

8 (4.8)

  Other

7 (10.3)

4 (5.2)

7 (5.5)

8 (6.6)

14 (7.1)

12 (6.0)

21 (12.5)

7 (4.2)

Lenalidomide dose skipped, n (%)

50 (73.5)

47 (61.0)

101 (78.9)

78 (63.9)

151 (77.0)

125 (62.8)

140 (83.3)

109 (65.7)

 Reason for skipping, n (%)

        

  AE

39 (57.4)

32 (41.6)

85 (66.4)

66 (54.1)

124 (63.3)

98 (49.2)

117 (69.6)

77 (46.4)

  Other

30 (44.1)

31 (40.3)

54 (42.2)

41 (33.6)

84 (42.9)

72 (36.2)

81 (48.2)

66 (39.8)

Lenalidomide dose reduced, n (%)

53 (77.9)

40 (51.9)

83 (64.8)

70 (57.4)

136 (69.4)

110 (55.3)

118 (70.2)

88 (53.0)

 Reason for reduction, n (%)

        

  AE

51 (75.0)

38 (49.4)

74 (57.8)

63 (51.6)

125 (63.8)

101 (50.8)

108 (64.3)

73 (44.0)

  Other

3 (4.4)

4 (5.2)

13 (10.2)

11 (9.0)

16 (8.2)

15 (7.5)

22 (13.1)

24 (14.5)

  1. D-Rd daratumumab plus lenalidomide/dexamethasone, Rd lenalidomide/dexamethasone, AE adverse event.
  2. aPercentages in the table were calculated using the number of patients in each treatment cohort per frailty subgroup of the safety population (fit: D-Rd, n = 68; Rd, n = 77; intermediate: D-Rd, n = 128; Rd, n = 122; total–non-frail: D-Rd, n = 196; Rd, n = 199; frail: D-Rd, n = 168; Rd, n = 166) as the denominator, unless otherwise indicated.
  3. bNon-frail subgroup consists of fit and intermediate patients.
  4. cPercentage was calculated using the number of patients in the safety population as the denominator.
  5. dPercentage was calculated using the number of patients in the D-Rd cohort of the safety population as the denominator.
  6. ePercentage was calculated using the number of patients in the Rd cohort of the safety population as the denominator.
Back to article page